bug-hurd
[Top][All Lists]
Advanced

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Merrill can’t buy enough


From: Meghan Sizemore
Subject: Merrill can’t buy enough
Date: Wed, 22 Jun 2005 21:03:31 -0600



 

 

EMERGING GROWTH ALERT

Issue: 1006177
June 2005
Pingchuan Pharmaceutical Inc
Undervalued Special Situation
Symbol: PGCN
52 Week Range 0.15 - 4.00
Shares Float: 25,000,000
Current Price: $4.75 
12 Mo.Target Price $26.00
 Last 5 days gain $3.40

Breaking News Alerts!

Big News Expected  Thursday  Jun  22 
Value should climb quickly!  Be ready for the ride of your life, as you can see so far 

PR Newswire (Tue, Jun 14)
Pingchuan Signs Regional Distribution Contract With Beijing Pingchuan Tianzhi Medical Technology Development Center

EDGAR Online (Mon, May 23)

PINGCHUAN PHARMACEUTICAL INC Files SEC form 10QSB, Quarterly Report

CORPORATE PROFILE :
 Pingchuan Pharmaceutical Inc. (''PGCN'') is a modernized pharmaceutical manufacturer with first-class medical R&D ability, pioneered medicine products, and well-established marketing network. Since its establishment, PGCN has focused its businesses on diabetes medicine and its medical products. The products of PGCN include health care products, varieties of medicine, as well as medical apparatus. Kang Da Glycosuria Capsule is a successful product of PGCN for treating diabetes, which was first developed in 1998 and introduced to the market in 2001. PGCN has well-established marketing network and sale branches, which include about 180,000 retail pharmacies/drugstores across China, agency network in major cities like Beijing, Shanghai, Guangzhou, and Xi'an, special counter sale at drug chain stores in key regions, residence community clinic sale and promotion, as well as internet marketing through the company's website. The marketing network of PGCN covers more than 50% districts of China and exports to US, Japan, Russia, and south-eastern Asia.

About Beijing Pingchuan Tianzhi Medical Technology Development Center

Beijing Pingchuan Tianzhi Medical Technology Development is grouped under Harbin Pingchuan Pharmaceutical Co., Ltd. in Jan. 2000. It is a wholly-owned subsidiary of Harbin Pingchuan Pharmaceutical Company. TIANZHI focuses on dealing with self-produced products, as well as dealing & distributing other medicines, health cares, pharmaceutical apparatuses and international trade businesses TIANZHI was authorized as the exclusive agent for the product of Kangda'an sugar capsule in Beijing area. By the end of 2004, TIANZHI printed out its good result that the total number of medicine bottles sold out was 26,000 and the sales revenue in 2004 was RMB400,000.


PGCN is getting ready to break out. We recommend this as a VERY strong buy.

     

     

     

     

     

     

     

     

     

     

    after a little girl whose mother was killed by the tsunami gave him a picture showing her village being struck by the giant waves Mr Clinton also came close to tears after receiving a similar drawing from another child in the village which lost half of its population at least 2500 people I don't think there's woundedPolice said that



    reply via email to

    [Prev in Thread] Current Thread [Next in Thread]